Filip Janku - 31 Oct 2022 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Chief Medical Officer
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Issuer symbol
GLUE
Transactions as of
31 Oct 2022
Net transactions value
$0
Form type
4
Filing time
01 Nov 2022, 16:30:31 UTC
Previous filing
02 Mar 2022
Next filing
19 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +36,000 $0.000000 36,000 31 Oct 2022 Common Stock 36,000 $7.56 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 3, 2022, the Reporting Person was granted an option to purchase 36,000 shares of Common Stock, subject to the satisfaction of certain performance criteria. On October 31, 2022, the performance criteria underlying such shares were met.
F2 The shares underlying this option shall vest in full on April 30, 2024, subject to the Reporting Person's continued service on such date.